Key facts
- It has raised $14.3M; the latest was Later Stage VC in Jan 2026.
- Notable investors include HSG (Hong Kong), Suzhou Guofa Venture Capital, Beijing State-owned Capital Operation and Management, YuanBio Venture Capital, Tsing Stone Asset Management — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Chromai
- ·The full record, as it builds
Funding rounds
No funding rounds for Chromai are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Chromai
Developer of medical molecular diagnostics and testing technology designed to simplify the diagnostic and testing process. The company is committed to using a variety of technologies, including AI, BigData and IoT, combined with leading analysis and detection technologies, to devote themselves to the fields of health In Vitro Diagnostic (IVD), environmental protection, and scientific instruments, enabling medical users with simplified and efficient diagnostic and testing analysis.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2019
- Employees
- 21
- Website
- chromai.com/
- Ownership
- Privately Held (backing)
Chromai doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Chromai shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Chromai in its N-PORT filings yet. We sweep new filings monthly.